- Bicara Therapeutics (BCAX, Financial) to present updated Phase 1/1b trial data at the 2025 ASCO Annual Meeting.
- The study focuses on ficerafusp alfa for HPV-negative recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
- Presentation scheduled for June 1, 2025, in Chicago, IL.
Bicara Therapeutics Inc. (BCAX), a clinical-stage biopharmaceutical company, has announced its upcoming presentation of updated data from its ongoing Phase 1/1b clinical trial of ficerafusp alfa. The presentation will occur during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, from May 30 to June 3, 2025.
The focus of this oral presentation will be on the drug's efficacy in treating first-line recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), specifically targeting HPV-negative patients. These patients usually have a poorer prognosis and worse clinical outcomes compared to their HPV-positive counterparts.
Ficerafusp alfa is a first-in-class bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain targeting human transforming growth factor beta (TGF-?). This dual-targeting approach allows the drug to block both the EGFR-related survival and proliferation of cancer cells and the immunosuppressive signaling mediated by TGF-? in the tumor microenvironment.
The presentation will take place on June 1, 2025, at 12:12 PM CT, at the McCormick Place Convention Center, with additional details to be made available on Bicara's website following the meeting.
Bicara Therapeutics remains committed to advancing its development program for ficerafusp alfa in HNSCC, addressing the unmet needs of patients with difficult-to-treat solid tumors. Further information on Bicara Therapeutics can be found on their website or through their social media channels.
